Tissue pharmacokinetics of DHP107, a novel lipid-based oral formulation of paclitaxel, in mice and patients by positron emission tomography

Byung Seok Moon1, Hyun Soo Park2, Jung Sunwoo3, In-Hyun Lee4, Anhye Kim5, Seol Ju Moon6, Heechan Lee7, Min Hee Son4, Su Bin Kim2, Sun Mi Park1, Sang-Keun Woo8, Jun-Hee Jang4, Bom Sahn Kim1, Jee Hyun Kim9, Sang Eun Kim2,10,12, Howard Lee7,10,11,12

1Department of Nuclear Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea
2Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea
3Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
4Pan-gyo Research Laboratory, Daehwa Pharmaceutical Co. Ltd, Seongnam, Korea
5Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University, Seongnam, Korea
6Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Korea
7Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
8Division of RI-Convergence Research, Korea Institute Radiological and Medical Sciences, Seoul, Korea
9Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea
10Advanced Institutes of Convergence Technology, Suwon, Korea
11Center for Convergence Approaches in Drug Development, Seoul National University, Seoul, Korea
12Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea

Abstract

DHP107 is a newly developed lipid-based oral formulation of paclitaxel. We evaluated the in vivo tissue pharmacokinetics (PKs) of DHP107 in mice and patients using positron emission tomography (PET). Radioisotope-labeled [3H]DHP107 and [18F]DHP107 for oral administration were formulated in the same manner as the manufacturing process of DHP107. In vivo tissue PK were assessed in healthy ICR mice and breast cancer xenografted SCID mice. Two patients with metastatic breast cancer were clinically evaluated for absorption at the target lesion after internal absorbed dose estimation. Whole-body PET/computed tomography data were acquired in healthy and xenografted mice and in patients up to 10–24 h after administration. Tissue [18F]DHP107 signals were plotted against time and PK parameters were determined. The amounts of radioactivity in various organs and excreta were determined using a beta-counter and are expressed as the percentage of injected dose (ID). Oral...
INTRODUCTION

Paclitaxel is a clinically effective, but water-insoluble antitumor drug that is active against a broad spectrum of solid cancers, including lung, liver, and breast cancers. It is a substrate of P-glycoprotein (P-gp), an efflux transporter in the gastrointestinal epithelium. Therefore, paclitaxel was originally developed and is used as an i.v. formulation. However, the oral administration route is preferable for convenience and sustained exposure, which is more important than achieving a high concentration for the efficacy of cell-cycle phase-specific agents, such as paclitaxel.

DHP107 (Liporaxel; Daehwa Pharmaceutical, Korea) is a novel lipid-based oral formulation of paclitaxel. DHP107 is lipid-soluble and is systemically absorbed without the need for P-gp inhibitors or Cremophor EL. DHP107 is feasible, safe, and effective in patients with advanced malignancies refractory to standard treatments. DHP107 was efficacious in patients with metastatic solid tumors and recurrent gastric cancer in phase I/IIa and III studies. Furthermore, the interindividual variability of paclitaxel exposure after DHP107 was comparable to that of paclitaxel injection; the coefficient of variation of the area under the concentration-time curve until the last measurable concentration (AUC_last) of paclitaxel after administration of DHP107 (60–600 mg/m²) ranged from 11.8 to 34.0%, which was close to the 24.4% for i.v. paclitaxel at 175 mg/m².

Drug concentrations in the blood may not reflect those in tissues. If concentrations in blood and tissues are available, tissue–blood pharmacokinetic (PK) modeling may help optimize the drug dosage regimen. However, the in vivo time-course of DHP107 in tissues, particularly in the target tissue (i.e., tumors), has not been studied in humans.

Positron emission tomography (PET) studies using radioisotope-labeled drugs can provide information on drug properties by exploring the tissue pharmacokinetics in early drug development.
DHP107, which was in clinical trial at the time. We analyzed [1H]DHP107 distribution in mice using a beta-counter to validate the PET PKs of [18F]DHP107 and methodological limitations that can be argued for whether PKs are equivalent between microdose and therapeutic doses are discussed based on the results obtained from experimental validation. An exploratory PET clinical trial was conducted in patients with hormone receptor (HR)-positive and HER2-negative metastatic breast cancer to determine whether the findings in preclinical assessment could be extrapolated to humans.

MATERIALS AND METHODS

Preparation of [18F]DHP107 and [3H]DHP107

[18F]Paclitaxel was prepared by conventional Kryptofix-mediated nucleophilic aromatic 18F-substitution on the trimethylammonium triflate-leaving group of the precursor through three steps (Figure S1) in the modified TRACERlab FX N Pro module (GE Healthcare; Figure S2), with a slight modification according to the literature. For formulation of [18F]paclitaxel for oral administration (named [18F]DHP107), finally obtained absolute ethanol solution containing [18F]paclitaxel (~370 MBq/0.1 ml) was mixed with glyceryl monooleate. After vortexing for 10 s, most of the ethanol was removed by nitrogen gas streaming at 40°C for 20 min, and then, glycerin fatty acid ester and polysorbate 80 were added sequentially. All formulation processes were the same as for the manufacturing of DHP107. For the clinical study, the process was carried out in a biosafety cabinet with real-time environmental monitoring of airborne particles in 1 m³ air and microbial contaminations (air sample, settle plates, contact plates, and glove print 5 fingers). Preparations were carried out in a grade A environment. Quality assays for the clinical study met the criteria set by the Korean Ministry of Food and Drug Safety (MFDS), including visual inspection, foreign insoluble matter test, radionuclide identity, radiochemical and chemical purities, and determination of radioactive concentration. Next, to obtain [3H]paclitaxel for oral administration (named [3H]DHP107), it was manufactured using [3H]paclitaxel in ethanol (purity: >97%, specific activity: 20–40 Ci/mmol; Moravek) according to the [18F] DHP107 manufacturing process described above.

Animals

Animal studies were conducted in accordance with institutional guidelines, and protocols were approved by the Animal Ethics Committee of Seoul National University Bundang Hospital (BA1608-206/049-01, August 9, 2016). To study the in vivo tissue PK of [18F]- and [3H]DHP107, 6-week-old female ICR mice (Orient Bio, Gyeonggi-do, Korea) were used. The mice were housed individually, with ad libitum access to water and food (AIN 93G formula) in a controlled environment (24 ± 2°C, 40 ± 2% humidity, 12-h light/dark cycle). To study target tissue (i.e., tumor) PK, HER2-overexpressing SK-BR3 tumor-bearing SCID mice (Orient Bio) were used.

Human participants

An open-label, exploratory clinical study was conducted in two patients with metastatic breast cancer who received a single oral dose of DHP107 at 200 mg/m² and [18F]DHP107 with a radioactivity of 185–555 MBq at a microdose (0.98–2.9 μg calculated from molar activity). Written informed consent was obtained from the patients. Patients aged greater than 19 years, diagnosed with solid cancer on histopathology or cytology, and with progressed, metastatic, or recurrent disease despite standard therapies for solid tumors were eligible. The disease had to be measurable according to the Response Evaluation Criteria in Solid Tumors version 1.1. The Eastern Cooperative Oncology Group performance status should be less than 2 and the expected survival time should be greater than or equal to 12 weeks. The study protocol was approved by the MFDS and the Institutional Review Board of Seoul National University Bundang Hospital (B-1706/403-001, ClinicalTrials.gov identifier: NCT04046016).

Preclinical PET study

After fasting around 9 h (free access to water), [18F]DHP107 (10.9 ± 0.29 MBq in 0.1 mL) was orally administrated to ICR mice (22.2 ± 0.3 g, n = 6, 10.9 ± 0.38 MBq/0.1 mL, co-administered with 50 mg/kg of DHP107) and SK-BR3 tumor-bearing SCID mice (G1; 17.2 ± 0.9 g, n = 4, 10.8 ± 0.63 MBq/0.1 mL) for therapeutic-dose group co-administered with 50 mg/kg of DHP107 and G2; 17.6 ± 1.4 g, n = 4, 10.3 ± 0.87 MBq/0.1 mL for micro-dose group without DHP107, respectively) using a disposable feeding needle coupled with a 1-ml syringe. Whole-body PET/computed tomography (CT) data were acquired at 0.5, 1, 3, 7, and 12 h postadministration (up to 24 h for ICR mice). The [18F]DHP107 distribution was determined using whole-body PET images, and time–radioactivity profiles were generated for each organ of interest. Canvas images of volume-of-interest (VOI) drawings were chosen between CT and PET images, depending on organ visibility and mobility. VOIs for the liver, lungs, spleen, brain, stomach, heart, and kidneys were drawn on CT images of individual subject in a slice-by-slice manner, whereas those for the gallbladder, intestine, and urinary bladder were drawn on averaged PET images by adjusting iso-contour VOIs. The amount of radioactivity in each organ was calculated as the % injected dose (ID) using the following
formulas: %ID = ([total activity in organ] / [activity orally administered]) × 100. The following PK parameters of [18F]DHP107 in each organ were quantitatively assessed based on the time–concentration profiles of the organs of interest: peak concentration (Cmax), time to reach Cmax (Tmax), terminal half-life (T1/2), and AUC from time 0 to 24 h (AUC0–24h). PET image analysis was performed using PMOD software version 3.1 (PMOD Technologies, Zurich, Switzerland). PK parameters were calculated using GraphPad Prism version 8.0 (GraphPad Software).

Clinical PET study

After a greater than 6-h water fast, subjects were brought to the PET center of Seoul National University Bundang Hospital 2 h before the scan. Head and limbs were fastened to prevent movement during the scan. Subjects underwent five whole-body PET scans at 0.5, 2, 4, 8, and 10 h after oral administration of microdose [18F]DHP107 and therapeutic dose of DHP107 (200 mg/m², the dose used in phase III).7 The administered radioactivity of [18F]DHP107 was 418.1 MBq for one subject and 290.0 MBq for the other. The injected mass of [18F]DHP107 was ~ 2.22 μg and 1.54 μg, respectively, calculated from the molar activity at the end of synthesis. A low-dose helical CT scan was conducted prior to the PET scan. Measurement of [18F]DHP107 distribution for each organ of interest was performed in the manner previously described. The radioactivity concentration of [18F]DHP107 in organs was expressed as %ID, and Cmax, Tmax, and AUC were estimated. T1/2 was estimated by nonlinear least square curve fitting using the multiple exponential function in GraphPad Prism version 8.0. For plasma PK analysis, blood samples were collected using sodium-heparin-laced tubes at 0, 2, 4, 8, and 10 h after administration. Plasma concentrations of DHP107 were determined by liquid chromatography-tandem mass spectrometry using an Agilent 260 Infinity system (Agilent Technologies) and API4000 (AB SCIEX). Standard curves for DHP107 were linear over 0.75–600 ng/ml, with a lower limit of quantification of 0.75 ng/ml. The Cmax, Tmax, AUC from 0 to the last measurable time (AUClast), AUC from 0 to infinity (AUC∞), and t1/2 were estimated by the noncompartmental method using Phoenix WinNonlin version 8.0.

Internal dosimetry of experimental animals

Internal dosimetry of experimental animals was performed using an image-based approach with the Monte Carlo N-Particle Code, according to ref. 16. Based on PET images at 0.5, 1, 3, 7, 12, and 24 h after oral administration (ICR mice, 22.2 ± 0.3 g, n = 6, 10.9 ± 0.38 MBq), the residence time was calculated based on the time-activity curve of region-segmented PET data. The human absorbed dose of [18F]DHP107 for approval of exploratory PET clinical trial from the MFDS was estimated by the adult S value and its residence times.

Beta-counter study

The ex vivo biodistribution of [3H]DHP107 at a therapeutic dose was assessed using ICR mice (21.9 ± 0.4 g, n = 4 at each point: 0.5, 1, 2, 4, 8, 12, 24, and 48 h after administration). After a greater than 9-h water fast, [3H]DHP107 (0.93 MBq/0.1 ml, co-administered with 50 mg/kg of DHP107) was orally administered using a disposable feeding needle. The animals were killed by cervical dislocation at the indicated timepoints, and organs were harvested. Another 6 animals were used to evaluate the amount of radioactivity excreted via the feces and urine for 48 h after oral administration of [3H]DHP107 (25 µCi/100 µl) at a therapeutic dose. Feces and urine were collected every 12 h using cleaning wipes. Radioactivity in the dissected organs and excreta was measured using a beta-counter after homogenization and dilution with a cocktail solution to amplify the signal. The amount of radioactivity was expressed as %ID.

RESULTS

Preparation of [18F]DHP107 and [3H]DHP107

The [18F]paclitaxel was synthesized by nucleophilic aromatic substitution by fluorine-18 on pentamethylbenzyl trimethylammoniumbenzoate, followed by hydrolysis with lithium hydroxide to obtain [18F]fluorobenzoic acid. Treatment of [18F]fluorobenzoic acid and N-debenzyol paclitaxel with N,N-diisopropylethylamine and diethyl cyanophosphonate resulted in amide formation to the desired [18F]paclitaxel. The total time for radiosynthesis was ~ 110 min, and the radioactivity yield after high-performance liquid chromatography purification was 6.8 ± 1.6% (Figure S3, n = 24, non-decay-corrected). The radiochemical purity was greater than 99%, and the identity was confirmed by co-injection with standard paclitaxel (Figure S4). The specific radioactivity at the end of synthesis was 164 ± 39 GBq/µmol. No significant radiolysis of [18F]paclitaxel in absolute ethanol was observed after 4 h at room temperature. Similarly, [18F]DHP107 showed no significant radiolysis after 2 h at room temperature. The [18F]DHP107 used in the clinical study met the quality control criteria for clinical studies set by the MFDS (Table S1). The [3H]DHP107, obtained following the [18F]DHP107 process from [3H]paclitaxel dissolved in ethanol, was not notably different from [18F]DHP107.
TISSUE PHARMACOKINETICS OF DHP107

Preclinical In Vivo tissue PK

Initially, $[^{18}F]$DHP107 was mostly accumulated in the stomach (AUC$_{0-24}$ h = 749.3 ± 86.4%ID h) (Figures 1, 2 and Table S2). The AUC$_{0-24}$ h, stomach/AUC$_{0-24}$ h, remaining organs was 0.8. The $[^{18}F]$DHP107 had a $t_{1/2}$ of 27.3 ± 6.4 h in the stomach. The order in the distribution of $[^{18}F]$DHP107 was as follows: stomach, intestine, liver, gallbladder, kidneys, bladder, brain, lungs, and heart. Within 3 h of administration, the $[^{18}F]$DHP107 concentration was the highest in the liver ($C_{\text{max}} = 11.0\%$ ID, $T_{\text{max}} = 2.9$ h), kidneys ($C_{\text{max}} = 0.7\%$ ID, $T_{\text{max}} = 2.8$ h), lungs ($C_{\text{max}} = 0.1\%$ ID, $T_{\text{max}} = 2.8$ h), and heart ($C_{\text{max}} = 0.1\%$ID/g, $T_{\text{max}} = 1.8$ h) except for the stomach, the route of the administration. $[^{18}F]$DHP107 was distributed in most organs and was eliminated with the organs’ association and dissociation rates. A significant amount of radioactivity was distributed to the intestine, gallbladder, and liver, and oral $[^{18}F]$DHP107 was shown to undergo hepatic metabolism and to be excreted via the biliary route (AUC$_{0-24}$ h, gallbladder = 18.6%ID h). Of the total amount of orally administered $[^{18}F]$DHP107, 16.1% (= AUC$_{0-24}$ h, intestine+gallbladder/AUC$_{0-24}$ h, total organs $\times$100%) was excreted via the biliary route, whereas only ~0.9% (= AUC$_{0-24}$ h, urinary bladder+kidneys/AUC$_{0-24}$ h, total organs $\times$100%) was excreted in the urine.

FIGURE 1  Representative whole-body positron emission tomography/computed tomography images of $[^{18}F]$DHP107 at various time points after oral administration in healthy mice

FIGURE 2  Time-concentration profiles of oral $[^{18}F]$DHP107 (●) and $[^3H]$DHP107 (○) in organs of interest in healthy mice. %ID, percentage of injected dose

Preclinical In Vivo tissue PK

Initially, $[^{18}F]$DHP107 was mostly accumulated in the stomach (AUC$_{0-24}$ h = 749.3 ± 86.4%ID h) (Figures 1, 2 and Table S2). The AUC$_{0-24}$ h, stomach/AUC$_{0-24}$ h, remaining organs was 0.8. The $[^{18}F]$DHP107 had a $t_{1/2}$ of 27.3 ± 6.4 h in the stomach. The order in the distribution of $[^{18}F]$DHP107 was as follows: stomach, intestine, liver, gallbladder, kidneys, bladder, brain, lungs, and heart. Within 3 h of administration, the $[^{18}F]$DHP107 concentration was the highest in the liver ($C_{\text{max}} = 11.0\%$ ID, $T_{\text{max}} = 2.9$ h), kidneys ($C_{\text{max}} = 0.7\%$ ID, $T_{\text{max}} = 2.8$ h), lungs ($C_{\text{max}} = 0.1\%$ ID, $T_{\text{max}} = 2.8$ h), and heart ($C_{\text{max}} = 0.1\%$ID/g, $T_{\text{max}} = 1.8$ h) except for the stomach, the route of the administration. $[^{18}F]$DHP107 was distributed in most organs and was eliminated with the organs’ association and dissociation rates. A significant amount of radioactivity was distributed to the intestine, gallbladder, and liver, and oral $[^{18}F]$DHP107 was shown to undergo hepatic metabolism and to be excreted via the biliary route (AUC$_{0-24}$ h, gallbladder = 18.6%ID h). Of the total amount of orally administered $[^{18}F]$DHP107, 16.1% (= AUC$_{0-24}$ h, intestine+gallbladder/AUC$_{0-24}$ h, total organs $\times$100%) was excreted via the biliary route, whereas only ~0.9% (= AUC$_{0-24}$ h, urinary bladder+kidneys/AUC$_{0-24}$ h, total organs $\times$100%) was excreted in the urine.

FIGURE 1  Representative whole-body positron emission tomography/computed tomography images of $[^{18}F]$DHP107 at various time points after oral administration in healthy mice

FIGURE 2  Time-concentration profiles of oral $[^{18}F]$DHP107 (●) and $[^3H]$DHP107 (○) in organs of interest in healthy mice. %ID, percentage of injected dose

Preclinical In Vivo tissue PK

Initially, $[^{18}F]$DHP107 was mostly accumulated in the stomach (AUC$_{0-24}$ h = 749.3 ± 86.4%ID h) (Figures 1, 2 and Table S2). The AUC$_{0-24}$ h, stomach/AUC$_{0-24}$ h, remaining organs was 0.8. The $[^{18}F]$DHP107 had a $t_{1/2}$ of 27.3 ± 6.4 h in the stomach. The order in the distribution of $[^{18}F]$DHP107 was as follows: stomach, intestine, liver, gallbladder, kidneys, bladder, brain, lungs, and heart. Within 3 h of administration, the $[^{18}F]$DHP107 concentration was the highest in the liver ($C_{\text{max}} = 11.0\%$ ID, $T_{\text{max}} = 2.9$ h), kidneys ($C_{\text{max}} = 0.7\%$ ID, $T_{\text{max}} = 2.8$ h), lungs ($C_{\text{max}} = 0.1\%$ ID, $T_{\text{max}} = 2.8$ h), and heart ($C_{\text{max}} = 0.1\%$ID/g, $T_{\text{max}} = 1.8$ h) except for the stomach, the route of the administration. $[^{18}F]$DHP107 was distributed in most organs and was eliminated with the organs’ association and dissociation rates. A significant amount of radioactivity was distributed to the intestine, gallbladder, and liver, and oral $[^{18}F]$DHP107 was shown to undergo hepatic metabolism and to be excreted via the biliary route (AUC$_{0-24}$ h, gallbladder = 18.6%ID h). Of the total amount of orally administered $[^{18}F]$DHP107, 16.1% (= AUC$_{0-24}$ h, intestine+gallbladder/AUC$_{0-24}$ h, total organs $\times$100%) was excreted via the biliary route, whereas only ~0.9% (= AUC$_{0-24}$ h, urinary bladder+kidneys/AUC$_{0-24}$ h, total organs $\times$100%) was excreted in the urine.

FIGURE 1  Representative whole-body positron emission tomography/computed tomography images of $[^{18}F]$DHP107 at various time points after oral administration in healthy mice

FIGURE 2  Time-concentration profiles of oral $[^{18}F]$DHP107 (●) and $[^3H]$DHP107 (○) in organs of interest in healthy mice. %ID, percentage of injected dose

Preclinical In Vivo tissue PK

Initially, $[^{18}F]$DHP107 was mostly accumulated in the stomach (AUC$_{0-24}$ h = 749.3 ± 86.4%ID h) (Figures 1, 2 and Table S2). The AUC$_{0-24}$ h, stomach/AUC$_{0-24}$ h, remaining organs was 0.8. The $[^{18}F]$DHP107 had a $t_{1/2}$ of 27.3 ± 6.4 h in the stomach. The order in the distribution of $[^{18}F]$DHP107 was as follows: stomach, intestine, liver, gallbladder, kidneys, bladder, brain, lungs, and heart. Within 3 h of administration, the $[^{18}F]$DHP107 concentration was the highest in the liver ($C_{\text{max}} = 11.0\%$ ID, $T_{\text{max}} = 2.9$ h), kidneys ($C_{\text{max}} = 0.7\%$ ID, $T_{\text{max}} = 2.8$ h), lungs ($C_{\text{max}} = 0.1\%$ ID, $T_{\text{max}} = 2.8$ h), and heart ($C_{\text{max}} = 0.1\%$ID/g, $T_{\text{max}} = 1.8$ h) except for the stomach, the route of the administration. $[^{18}F]$DHP107 was distributed in most organs and was eliminated with the organs’ association and dissociation rates. A significant amount of radioactivity was distributed to the intestine, gallbladder, and liver, and oral $[^{18}F]$DHP107 was shown to undergo hepatic metabolism and to be excreted via the biliary route (AUC$_{0-24}$ h, gallbladder = 18.6%ID h). Of the total amount of orally administered $[^{18}F]$DHP107, 16.1% (= AUC$_{0-24}$ h, intestine+gallbladder/AUC$_{0-24}$ h, total organs $\times$100%) was excreted via the biliary route, whereas only ~0.9% (= AUC$_{0-24}$ h, urinary bladder+kidneys/AUC$_{0-24}$ h, total organs $\times$100%) was excreted in the urine.
The in vivo tumor PKs of [18F]DHP107 in HER2-overexpressing SK-BR3 subcutaneous xenograft-bearing SCID mice were successfully visualized and assessed by PET (Figure 3). The [18F]DHP107 attained peak distribution to the tumor with C<sub>max</sub> of 0.80%ID and T<sub>max</sub> of 5.67 h and 7.33 h in G1 (+10 mg/kg DHP107) and G2 (without DHP107), respectively. Regardless of the co-administration of DHP107, the total accumulation of radioactivity was comparable between G1 and G2, with AUC<sub>0-12h</sub> of 6.83%ID h and 5.64%ID h, respectively (Table S3).

Absorbed dose calculation

The highest absorbed dose was detected in the stomach, with 6.15E-02 mSv/MBq (Table S6). The effective doses of [18F]-2-fluoro-2-deoxy-D-glucose ([18F]FDG), most widely used clinically in nuclear medicine, and [18F]DHP107 in adults are 4.64E-02 mSv/MBq and 6.56E-02 mSv/MBq, respectively. The radiation dose of [18F]DHP107 was slightly higher than that of [18F]FDG, but it might be safe at a similar dose.

In Vivo tissue PK in patients with metastatic breast cancer

The age and weight of two female subjects were 70 and 62 years old, 56.0 and 59.4 kg, respectively. In the patient with metastatic lesions in the sternum, right paratracheal lymph nodes, lungs, right seventh and eighth ribs, and T-spines, [18F]DHP107 distribution was the highest at 4.7 h, with the largest tumor lesion found in the sternum (Figure 4A). In the left lower-lobe lung metastasis, peak distribution was achieved readily (i.e., at the first time point) after administration. In the patient with tumors in the left breast, other tumors in the right breast, and metastases to the liver and right kidney, [18F]DHP107 distribution was the highest at 4.7 and 8.9 h in both primary breast tumor lesions (Figure 4B). In both patients, [18F]DHP107 was predominantly distributed in the stomach and intestine. The kidneys, lungs, and heart had less than 4.0%ID at all timepoints (Figure 4C, Table S7). [18F]DHP107 uptake by major organs and tissues was similar to that in the preclinical studies.

DHP107 plasma concentrations exceeded the lower limit of quantification until 10 h after administration in both patients. DHP107 was rapidly absorbed with T<sub>max</sub> of 2.0 and 2.25 h and C<sub>max</sub> of 373.2 and 538.8 ng/ml, respectively. The plasma t<sub>1/2</sub> of DHP107 was 2.0–2.5 h (Table S8).
Safety and tolerability

The patients received 10 and 9 cycles of DHP107 therapy, respectively, and both achieved clinical benefit (stable disease > 6 months). Each cycle was 28 days, and 200 mg/m² of DHP107 was administered twice daily on days 1, 8, and 15. DHP107 was tolerated well, without serious adverse events. The adverse events included grade 1 and 2 peripheral neuropathy, paronychia, alopecia, myalgia, skin rash, and diarrhea. Grade 3 neutropenia was the only grade 3/4 adverse event.

DISCUSSION

Information on drug absorption, distribution, metabolism, and excretion is imperative for understanding PK properties after administration. To predict drug safety and effectiveness, it is important to gather information on drug distribution by determining the extent to which drugs migrate from the blood to tissues and cells, and the extent to which they reach systemic organs, target organs, and tissues. As drug distribution and behavior cannot easily be observed in vivo, information is generally inferred from drug concentrations in the blood. Bioimaging technologies, such as PET, have attracted attention for evaluating drug distribution in vivo.5,11,13,18 Our study demonstrated the utility and uniqueness of PET in drug development, particularly in early clinical trials and proof-of-concept studies. PET is firmly established as a key three-dimensional medical imaging technique in the clinic.19 PET with radioisotope-labeled drugs can provide PK information that cannot be obtained from conventional blood PK studies.

DHP107 is a lipid-based oral paclitaxel formulation. Paclitaxel i.v. is widely used alone or in combination for the treatment of various cancers, but it has limited absorption and causes side effects and patient discomfort. DHP107 is expected to have increased drug absorption, less side effects, and easier administration than existing formulations. We investigated the systemic distribution of DHP107 by administering a therapeutic dose of DHP107 containing [18F] DHP107 in tumor-bearing mice and patients with metastatic breast cancer. The utility of PET/CT bioimaging after the administration of radioisotope-labeled drugs was evaluated.

FIGURE 4 Representative whole-body positron emission tomography (PET)/computed tomography (CT) images and timecourse of oral [18F] DHP107 distribution in clinical subjects (B, brain; Lg, lungs; H, heart; Lv, liver; G, gallbladder; S, stomach; I, intestine; UB, urinary bladder; T, tumor; R, right). All values are decay-corrected for the physical half-life of F-18. (a) PET/CT images of [18F]DHP107 in subject 1. (b) PET/CT images of [18F]DHP107 in subject 2. (c) Timecourse of oral [18F]DHP107 distribution in clinical subjects (●, subject 1; ○, subject 2). %ID, percentage of injected dose.
We successfully labeled DHP107 with $^3$H and $^{18}$F and orally administered these formulations in mice and patients ([$^{18}$F]DHP107 only in the latter). PET/CT images adequately showed the distribution of radioisotope-labeled DHP107 in organs and target tissues. In accordance with findings in previous studies, we demonstrated that oral DHP107 was absorbed and distributed in target organs in mice. In patients with metastatic breast cancer, DHP107 was well-absorbed through the intestinal tract and steadily reached tumor lesions, and the drug was well-tolerated at a 200 mg/m² dose. Taken together, our results demonstrate that DHP107 is well-tolerated and readily absorbed through the gastrointestinal tract, reaches the target lesion, and exhibits clinical anticancer efficacy, as shown in a clinical study.

The in vivo tumor PK of oral [$^{18}$F]DHP107 and i.v. [$^{18}$F]paclitaxel in HER2-overexpressing SK-BR3 subcutaneous xenograft mice were visualized and quantitatively assessed by PET. Oral [$^{18}$F]DHP107 accumulated in the tumors for 12 h (AUC$_{0-12}$ = 5.66%ID h) and reached the highest distribution concentration with C$_{max}$ = 0.66%ID and T$_{max}$ = 7.33 h. In contrast, the tumor distribution of i.v. [$^{18}$F]paclitaxel decreased immediately after until 12 h after administration, from 0.6%ID to 0.2%ID, resulting in an AUC$_{0-12}$ of 3.86%ID h (Table S9). The greater AUC for oral DHP107 than for i.v. [$^{18}$F]paclitaxel suggests that DHP107 may have a superior targeting ability in HER2-overexpressing tumors and that this drug, which has been approved by the MFDS for gastric cancer, may also be used for the treatment of HER2-positive breast cancer.

Plasma PK analysis revealed that DHP107 was well-absorbed in patients with metastatic breast cancer (T$_{max}$ = 2–2.5 h), which was consistent with findings in a previous human PK study (T$_{max}$ = 2.4–3.6 h). However, the plasma t$_{1/2}$ of DHP107 was 2.0–2.5 h, which was substantially shorter than that in the previous study (15.3–24.2 h). This is probably because we collected blood samples only up to 10 h after dosing, as opposed to the 48 h postadministration in the previous study. In addition, according to our previous report, the PK parameters, such as T$_{max}$, C$_{max}$, and AUC, of paclitaxel based on high-performance liquid chromatography (HPLC) using a semimicro-HPLC system in each organ was similar to that of paclitaxel acquired by PET.

Nevertheless, our study had limitations. First, clinical PK evaluation was conducted only in two patients, and only for HR-positive HER2-negative metastatic breast cancer. However, tissue distribution images were clearly and consistently obtained in both patients and confirmed that oral DHP107 reached the target lesions. Second, the number of subjects was too small to generalize the efficacy of DHP107. However, it is very likely that patients will benefit from DHP107 because it reaches the target lesion and its anticancer efficacy has been demonstrated. Finally, in the present study, no serious adverse event was reported from the participants. Radiation exposure demanding potential hazardous to the participants by [$^{18}$F]DHP107 administered orally (effective dose: 1.41E-02 mSv/MBq, equally for both patients) was comparable to the average effective dose from whole-body [$^{18}$F]FDG administration (Table S10).

**CONCLUSIONS**

[$^{18}$F]DHP107 was well-absorbed through the gastrointestinal tract following oral administration, accumulated in the target lesion in mice and patients with breast cancer, and was found to be safe. This study showed that PET using radioisotope-labeled drug candidates is useful in drug development and can complement plasma PK data, especially in early clinical trials.

**CONFLICTS OF INTEREST**

The authors declare no potential conflicts of interest.

**AUTHOR CONTRIBUTIONS**

B.S.M., H.S.P., J.S., J.H.K., S.E.K., and H.L. wrote the manuscript. B.S.M., H.S.P., J.S., J.H.K., S.E.K., and H.L. designed the research. B.S.M., H.S.P., J.S., J.H.K., S.E.K., H.L., I.H.L., A.K., S.J.M, Hc.L., M.H.S., S.B.K., S.M.P., S.K.W., J.H.J., and B.S.K. performed the research. B.S.M., H.S.P., J.S., S.B.K., S.M.P., and S.K.W. analyzed the data. B.S.M., H.S.P., J.S., J.H.K., S.E.K., and H.L. contributed new reagents/analytical tools.

**REFERENCES**

1. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA. 1997;94:2031-2035.
2. Liebmann J, Cook J, Lipschultz C, Teague D, Fisher J, Mitchell J. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer. 1993;68:1104-1109.
3. Kang Y-K, Ryu M-H, Park SH, et al. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018;29:1220-1226.
4. Hong YS, Kim K-P, Lim H-S, et al. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel. Invest New Drugs. 2013;31:616-622.
5. Lim H-S, Bae K-S, Jung J-A, et al. Predicting the efficacy of an oral paclitaxel formulation (DHP107) through modeling and simulation. Clin Ther. 2015;37:402-417.
6. Ryu M-H, Ryoo B-Y, Kim TW, et al. A phase I/IIa study of DHP107, a novel oral paclitaxel formulation, in patients with advanced solid tumors or gastric cancer. Oncologist. 2017;22:129-8.
7. Kang Y-K, Ryu M-H, Park SH, et al. Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy. *Am Soc Clin Oncol*. 2016;29:1220-1226.

8. Bauer M, Wagner CC, Langer O. Microdosing studies in humans: the role of positron emission tomography. *Drugs Res*. 2008;9:73-81.

9. Bergstrom M, Grahnenn A, Langstrom B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. *Eur J Clin Pharmacol*. 2003;59:357-366.

10. Wagner CC, Muller M, Lappin G, et al. Positron emission tomography for use in microdosing studies. *Curr Opin Drug Discov Devel*. 2008;11:104-110.

11. Fowler JS, Volkow ND, Wang GJ, et al. PET and drug research and development. *J Nucl Med*. 1999;40:1154-1163.

12. Klimas MT. Positron emission tomography and drug discovery: contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization. *Mol Imaging Biol*. 2002;4:311-337.

13. Park HS, Kim E, Moon BS, et al. In vivo tissue pharmacokinetics of carbon-11-labeled clozapine in healthy volunteers: a positron emission tomography study. *CPT Pharmacometrics Syst Pharmacol*. 2015;4:305-311.

14. Kalen JD, Hirsch JI, Kurdziel KA, et al. Automated synthesis of 18F analogue of paclitaxel (PAC):[18F] Paclitaxel (FPAC). *Appl Radiat Isot*. 2007;65:696-700.

15. Kiesewetter DO, Jagoda EM, Kao C-H, et al. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. *Nucl Med Biol*. 2003;30(1):11-24.

16. Woo S-K, Jang SJ, Seo M-J, et al. Development of 64Cu-NOTA-trastuzumab for HER2 targeting: a radiopharmaceutical with improved pharmacokinetics for human studies. *J Nucl Med*. 2019;60:26-33.

17. Kaushik A, Jaimini A, Tripathi M, et al. Estimation of radiation dose to patients from 18FDG whole body PET/CT investigations using dynamic PET scan protocol. *Indian J Med Res*. 2015;142:721.

18. Shin BS, Kim HJ, Hong SH, et al. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form. *Cancer Chemother Pharmacol*. 2009;64(1):87-94.

19. Hong JW, Lee I-H, Kwak YH, et al. Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. *Mol Cancer Ther*. 2007;6:3239-3247.

20. Jang Y, Ko MK, Park YE, et al. Effect of paclitaxel content in the DHP107 oral formulation on oral bioavailability and antitumor activity. *J Drug Deliv Sci Technol*. 2018;48:183-192.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article:** Moon BS, Park HS, Sunwoo J, et al. Tissue pharmacokinetics of DHP107, a novel lipid-based oral formulation of paclitaxel, in mice and patients by positron emission tomography. *Clin Transl Sci*. 2021;14:1747–1755. [https://doi.org/10.1111/cts.13003](https://doi.org/10.1111/cts.13003)